Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx (MDXG) Gross Margin (2016 - 2025)

Mimedx's Gross Margin history spans 15 years, with the latest figure at 83.86% for Q4 2025.

  • For Q4 2025, Gross Margin rose 206.0% year-over-year to 83.86%; the TTM value through Dec 2025 reached 82.56%, down 22.0%, while the annual FY2025 figure was 82.56%, 22.0% down from the prior year.
  • Gross Margin for Q4 2025 was 83.86% at Mimedx, roughly flat from 83.54% in the prior quarter.
  • Across five years, Gross Margin topped out at 86.03% in Q4 2021 and bottomed at 80.68% in Q4 2022.
  • The 5-year median for Gross Margin is 82.82% (2024), against an average of 82.81%.
  • The largest annual shift saw Gross Margin crashed -535bps in 2022 before it surged 338bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 86.03% in 2021, then dropped by -6bps to 80.68% in 2022, then increased by 4bps to 84.06% in 2023, then fell by -3bps to 81.8% in 2024, then increased by 3bps to 83.86% in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Gross Margin are 83.86% (Q4 2025), 83.54% (Q3 2025), and 81.05% (Q2 2025).